.png){kind=icon}
.png){kind=icon}
Return
Graves' disease
.png){kind=icon}
PRE
AI
DOI：10.1038/s41572-020-0184-y.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Graves' disease (GD) is an autoimmune disease that primarily affects the thyroid gland. It is the most common cause of hyperthyroidism and occurs at all ages but especially in women of reproductive age. Graves' hyperthyroidism is caused by autoantibodies to the thyroid-stimulating hormone receptor (TSHR) that act as agonists and induce excessive thyroid hormone secretion, releasing the thyroid gland from pituitary control. TSHR autoantibodies also underlie Graves' orbitopathy (GO) and pretibial myxoedema. Additionally, the pathophysiology of GO (and likely pretibial myxoedema) involves the synergism of insulin-like growth factor 1 receptor (IGF1R) with TSHR autoantibodies, causing retro-orbital tissue expansion and inflammation. Although the aetiology of GD remains unknown, evidence indicates a strong genetic component combined with random potential environmental insults in an immunologically susceptible individual. The treatment of GD has not changed substantially for many years and remains a choice between antithyroid drugs, radioiodine or surgery. However, antithyroid drug use can cause drug-induced embryopathy in pregnancy, radioiodine therapy can exacerbate GO and surgery can result in hypoparathyroidism or laryngeal nerve damage. Therefore, future studies should focus on improved drug management, and a number of important advances are on the horizon. Graves' disease is an autoimmune disease caused by autoantibodies to the thyroid-stimulating hormone receptor, causing hyperthyroidism. In this Primer, Davies and colleagues discuss the epidemiology, pathophysiology and diagnosis of Graves' disease and highlight the need for better therapeutics for its management.
Keywords:
QUALITY-OF-LIFE
AUTOIMMUNE THYROID-DISEASE
STIMULATING HORMONE-RECEPTOR
MODERATE-TO-SEVERE
MAJOR HISTOCOMPATIBILITY COMPLEX
HUMAN THYROTROPIN RECEPTOR
X-CHROMOSOME INACTIVATION
TSH-RECEPTOR
ANTITHYROID DRUGS
INTRAVENOUS GLUCOCORTICOIDS
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
N
IF:
60.6
Papers:
645
Citations:
3.8W
View more organizations